NCT01125293View on ClinicalTrials.gov

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

August 31, 2014

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Everolimus

DRUG

Rituximab

DRUG

Bortezomib

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER